Latest Breaking News On - University hospital clinic - Page 3 : comparemela.com

Phoenix Cardiac Receives CE Mark for its Innovative BACE Device to Treat Functional Mitral Regurgitation Company seeks partner to conduct a pivotal study in pursuit of a heart failure indication Clinical data supporting CE Mark to be presented as a late-breaking oral presentation at the virtual AATS 101 st annual meeting CARY, N.C., April 26, 2021 /PRNewswire/ Phoenix Cardiac Devices, Inc., an innovator in cardiovascular medical device research and development, today announced that it has received CE Mark for its BACE (Basal Annuloplasty of the Cardia Externally) device, a novel modality for the treatment of Functional Mitral Regurgitation (FMR). BACE is the only surgical device with long-term clinical data demonstrating significant benefit by addressing the root cause of FMR. The CE Mark serves as approval by the European Union (EU) to commercialize BACE. The supporting clinical data, showing significant efficacy in reduction of MR grade and size of the left ventricle that was

United statesAndhra pradeshJan hlavickaKostenloser wertpapierhandelGopal muppiralaPhoenix cardiac devices incUniversity hospital clinic for cardiovascular surgeryPhoenix cardiac incUniversity in frankfurt am mainPrnewswire phoenix cardiac devices incAmerican association for thoracic surgeryEuropean unionCardiac devicesBasal annuloplastyCardia externallyFunctional mitral regurgitation